Ovarian Cancer Trial, Recruiting NCT05927818 Sponsor: Istanbul University Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT05927818
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a suspicious growth or mass near the ovaries that doctors believe may be early-stage ovarian cancer.
  • People who are healthy enough, both medically and physically, to undergo a sentinel lymph node biopsy procedure and a full lymph node removal surgery.

Who may not be able to join:

  • People whose ovarian mass is considered unlikely to be early-stage ovarian cancer.
  • People who have medical or physical conditions that make comprehensive staging surgery unsafe or unsuitable for them.
  • People whose ovarian cancer has spread to other parts of the body, or who have a second, separate cancer occurring at a different time (confirm with trial site).
  • People who have had ovarian cancer that has come back after previous treatment.
  • People where surgery or pre-surgical assessment shows the cancer has already reached an advanced stage (known medically as FIGO Stage III or IV).
  • People who are receiving chemotherapy or other treatment before surgery to shrink the cancer first (sometimes called neoadjuvant treatment).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +90 532 687 10 51

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istanbul University
Registry
ClinicalTrials.gov
Start date
15 April 2023
Est. completion
15 October 2025

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Efficacy of sentinel lymph node biopsy in highly suspicious adnexal masses for early-stage ovarian cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov